A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

被引：2

作者：

Mazza, Irit Avivi ^{[1
,2
]}

Barba, Pere ^{[3
]}

Yuda, Junichiro ^{[4
]}

Palomba, Maria Lia ^{[5
]}

Alderuccio, Juan Pablo ^{[6
]}

de Vriendt, Ciel ^{[7
]}

Corradini, Paolo ^{[8
,9
]}

Lim, Francesca Lorraine Wei Inng ^{[10
]}

Zinzani, Pier Luigi ^{[11
]}

Jain, Nitin ^{[12
]}

Leonard, Jessica T. ^{[13
]}

Coulson, Michelle ^{[14
]}

Hassounah, Nadia ^{[14
]}

Yang, Xiaoling ^{[14
]}

Lu, Haihui ^{[14
]}

Lewandowski, Andrew ^{[14
]}

Polli, Joseph Ryan ^{[14
]}

Klopfenstein, Matthieu

Pastore, Alessandro ^{[15
]}

Brisou, Gabriel ^{[16
]}

机构：

[1] Tel Aviv Univ, BMT Unit, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[2] Tel Aviv Univ, Fac Med, Tel Aviv, Israel

[3] Vall DHebron Inst Oncol VHIO, Hosp Univ Vall DHebron, Deparment Hematol, La Garriga, Spain

[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[5] Mem Sloan Kettering Canc Ctr, Cellular Therapy Serv, New York, NY USA

[6] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[7] Univ Hosp Ghent Univ Ziekenhuis, Ghent, Belgium

[8] Univ Milan, Milan, Italy

[9] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[10] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore

[11] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[12] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[13] Oregon Hlth & Sci Univ, Dept Med Hematol Oncol, Portland, OR USA

[14] Novartis Inst BioMed Res, Cambridge, MA USA

[15] Novartis Inst BioMed Res, Basel, Switzerland

[16] Inst Paoli Calmettes, Dept Hematol, Marseille, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179061

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[41] Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study
Tun, Aung M.
Patel, Romil D.
St-Pierre, Frederique
Ouchveridze, Evguenia
Niu, Alex
Thordardottir, Thorunn
Obasi, Jennifer
Rosenthal, Allison
Pophali, Priyanka A.
Fenske, Timothy S.
Karmali, Reem
Ahmed, Sairah
Johnston, Patrick B.
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1712 - 1720
[42] Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies
Ryan, Maureen C.
Palanca-Wessels, Maria Corinna
Schimpf, Brian
Gordon, Kristine A.
Kostner, Heather
Meyer, Brad
Yu, Changpu
Van Epps, Heather A.
Benjamin, Dennis
BLOOD, 2017, 130 (18) : 2018 - 2026
[43] Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma
Oliai, Caspian
de Vos, Sven
BLOOD, 2019, 134
[44] The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma
Flavell, DJ
Warnes, SL
Bryson, CJ
Field, SA
Noss, AL
Packham, G
Flavell, SU
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (02) : 157 - 170
[45] DIFFERENTIAL IMMUNOMODULATION BY ANTI-CD2 MONOCLONAL-ANTIBODIES OF ANTI-CD3-INDUCED T-CELL ACTIVATION - DEPENDENCE UPON THE INDIVIDUAL ANTI-CD3 MONOCLONAL-ANTIBODY USED FOR ACTIVATION
STOHL, W
POSNETT, DN
CHIORAZZI, N
CELLULAR IMMUNOLOGY, 1988, 116 (01) : 73 - 85
[46] Efficacy of anti-CD19 CAR-T cell therapy in 10 refractory recurrent B cell malignancies
包芳
China Medical Abstracts(Internal Medicine), 2018, 35 (03) : 186 - 187
[47] Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy
Perez, Arianne
Navale, Lynn
Rossi, John M.
Shen, Yueh-wei
Jiang, Yizhou
Sherman, Marika
Mardiros, Armen
Yoder, Sean C.
Go, William Y.
Rosenberg, Steven A.
Wiezorek, Jeff
Roberts, Margo R.
Chang, David D.
Kochenderfer, James N.
Bot, Adrian
BLOOD, 2015, 126 (23)
[48] Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies
Shah, Nirav N.
Krishnan, Amrita Y.
Shah, Nina D.
Burke, John M.
Melear, Jason M.
Spira, Alexander I.
Popplewell, Leslie L.
Andreadis, Charalambos B.
Chhabra, Saurabh
Sharman, Jeff P.
Kaufman, Jonathan L.
Cohen, Jonathon B.
Niesvizky, Ruben
Martin, Thomas G., III
Dilea, Clifford
Kuriakose, Jason
Matheny, Shannon L.
Leonard, John P.
Molina, Arturo
BLOOD, 2019, 134
[49] INITIAL EXPERIENCE WITH TREATMENT OF HUMAN B-CELL LYMPHOMA WITH ANTI-CD19 MONOCLONAL-ANTIBODY
HEKMAN, A
HONSELAAR, A
VUIST, WMJ
SEIN, JJ
RODENHUIS, S
HUININK, WWT
SOMERS, R
RUMKE, P
MELIEF, CJM
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 32 (06) : 364 - 372
[50] IMMUNOTHERAPY OF RECURRENT B-CELL MALIGNANCIES IN ADULT AND PAEDIATRIC PATIENTS WITH FBTA05, A TRIFUNCTIONAL ANTIBODY (ANTI-CD3 X ANTI-CD20) AND ALLOGENEIC DONOR LYMPHOCYTE INFUSION
Buhmann, R.
Stanglmaier, M.
Schuster, F.
Simoes, B.
Menzel, H.
Ruf, P.
Peschel, C.
Lindhofer, H.
Borkhardt, A.
Kolb, H. J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 183 - 183

← 1 2 3 4 5 →